Investigator Perspectives

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how recent clinical trials, including ARASENS and ARANOTE, have expanded treatment options for metastatic prostate cancer, highlighting the efficacy and safety of combining darolutamide with androgen deprivation therapy and/or chemotherapy while considering patient-specific factors to guide individualized treatment decisions.

Pedro Barata, MD, MSc FACP, discusses how recent clinical trials have advanced the treatment of metastatic prostate cancer, focusing on the efficacy of combination therapies involving radium-223, AR-targeted agents, and PARP inhibitors, while addressing safety concerns and considering optimal treatment strategies for different patient populations.

Michael Gorin, MD explores the PSMA imaging landscape, emerging agents with extended imaging windows, key copper-based imaging trials, and the anticipated impact of next-day imaging pending CLARIFY trial results.

Gary D. Steinberg, MD, discusses recent clinical trial data presented at the AUA 2024 Conference, as well as practice-changing novel therapies for the treatment of intermediate and high risknon muscle invasive bladder cancer.

Neal Shore, MD, FACS, provides comprehensive insights on the evolving treatment landscape for patients with BCG-unresponsive non-muscle-invasive bladder cancer, with a focus on clinical research and treatment practices.

Daniel Allan Hamstra, MD, PhD, FASTRO, FASCO, details the currently available options for rectal spacers in patients with prostate cancer undergoing radiation therapy, and highlights the key clinical trial data leading to their approval for reducing toxicities and preserving sexual quality-of-life.

Expert urologist Michael S. Leapman, MD, MHS, considers how the Decipher Prostate Genomic Classifier and real-world data updates from the 2023 American Urological Association (AUA) Annual Meeting have impacted prostate cancer care.

Eric A. Singer, MD, MA, FACS, an expert urologic oncologist, discusses recent data from KEYNOTE-057 presented at the 2023 American Urological Association (AUA) Annual Meeting, and offers clinical insights on treatment paradigms for non-muscle-invasive bladder cancer.